# Revision of PRECAUTIONS

## Bosentan hydrate

November 26, 2025

### Therapeutic category

Other cardiovascular agents

### Non-proprietary name

Bosentan hydrate

### Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

| Current | Revision |
|---|---|
| 1. WARNINGS<br>This drug causes hepatic function disorder. Patients must undergo liver function tests before administration and at least once a month during administration. It is desirable for patients to undergo the test once every 2 weeks for 3 months after the start of administration. If any abnormality is observed in liver function test values, appropriate measures such as dose reduction or discontinuation of administration should be taken according to the severity and clinical symptoms. | 1. WARNINGS<br>This drug <u>may</u> cause hepatic function disorder <u>or autoimmune hepatitis</u>. Patients must undergo liver function tests before administration and at least once a month during administration. It is desirable for patients to undergo the test once every 2 weeks for 3 months after the start of administration. If any abnormality is observed in liver function test values, appropriate measures such as dose reduction or discontinuation of administration should be taken according to the severity and clinical symptoms. |
| 7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION<br>In the case where AST increased or ALT increased is accompanied by clinical symptoms of liver disorder, including queasy, vomiting, pyrexia, abdominal pain, jaundice, lethargy or fatigue, and flu-like symptoms (arthralgia, myalgia, pyrexia), or bilirubin level is 2 times the upper limit of the reference range or higher, administration should be discontinued. | 7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION<br>In the case where AST increased or ALT increased is accompanied by clinical symptoms of liver disorder <u>or autoimmune hepatitis</u>, including queasy, vomiting, pyrexia, abdominal pain, jaundice, lethargy or fatigue, and flu-like symptoms (arthralgia, myalgia, pyrexia), or bilirubin level is 2 times the upper limit of the reference range or higher, administration should be discontinued. |
| 11. ADVERSE REACTIONS<br>11.1 Clinically Significant Adverse Reactions<br>(newly added) | 11. ADVERSE REACTIONS<br>11.1 Clinically Significant Adverse Reactions<br><u>Autoimmune hepatitis</u><br><u>Autoimmune hepatitis may occur with a latency of a few months to years after the start of administration of this drug.</u> |